American Association for Cancer Research

Skip to Main Content

Table 2.

Association of serum APN/CD13 level with clinicopathologic variables

Factor	Serum APN/CD13 (units/mL)			P
Factor		High level (>6.5), n (%)	Low level (≤6.5), n (%)	P
Age (y)
≤70	14 (23.3)	46 (76.7)	0.160*
>70	3 (10.0)	27 (90.0)	0.160*
Sex
Female	3 (11.1)	24 (88.9)	0.256*
Male	14 (22.2)	49 (77.8)	0.256*
Performance status
0-2	11 (13.6)	70 (86.4)	0.001*
3, 4	6 (66.7)	3 (33.3)	0.001*
Stage
I-IIIA	0 (0)	27 (100)	0.004^†
IIIB	4 (13.6)	19 (86.4)
IV	13 (36.4)	27 (63.6)
Histologic type
Adenocarcinoma	15 (23.4)	49 (76.6)	0.136*
Nonadenocarcinoma	2 (7.7)	24 (92.3)	0.136*
Serum CEA
Normal	7 (17.1)	34 (82.9)	0.790*
More than normal	10 (20.4)	39 (79.6)	0.790*
Response to chemotherapy
PR	2 (14.3)	12 (85.7)	0.007*
SD	2 (13.3)	13 (86.7)		(PR + SD vs PD)
PD	7 (58.3)	5 (41.7)
Not evaluable	1 (50.0)	1 (50.0)

Factor	Serum APN/CD13 (units/mL)			P
Factor		High level (>6.5), n (%)	Low level (≤6.5), n (%)	P
Age (y)
≤70	14 (23.3)	46 (76.7)	0.160*
>70	3 (10.0)	27 (90.0)	0.160*
Sex
Female	3 (11.1)	24 (88.9)	0.256*
Male	14 (22.2)	49 (77.8)	0.256*
Performance status
0-2	11 (13.6)	70 (86.4)	0.001*
3, 4	6 (66.7)	3 (33.3)	0.001*
Stage
I-IIIA	0 (0)	27 (100)	0.004^†
IIIB	4 (13.6)	19 (86.4)
IV	13 (36.4)	27 (63.6)
Histologic type
Adenocarcinoma	15 (23.4)	49 (76.6)	0.136*
Nonadenocarcinoma	2 (7.7)	24 (92.3)	0.136*
Serum CEA
Normal	7 (17.1)	34 (82.9)	0.790*
More than normal	10 (20.4)	39 (79.6)	0.790*
Response to chemotherapy
PR	2 (14.3)	12 (85.7)	0.007*
SD	2 (13.3)	13 (86.7)		(PR + SD vs PD)
PD	7 (58.3)	5 (41.7)
Not evaluable	1 (50.0)	1 (50.0)

Abbreviations: APN, aminopeptidase N; CEA, carcinoembryonic antigen; PR, partial response; SD, stable disease; PD, progressive disease.

Fisher's exact test.

Mann-Whitney U test.